



MICROCONTAINERS FOR INTESTINAL DRUG DELIVERY: in vivo and ex vivo study

Mazzoni, Chiara; Tentor, Fabio; Andersen, Sophie Susanna Strindberg; Nielsen, Line Hagner; Keller, Stephan Sylvest; Müllertz, A.; Marizza, Paolo; Boisen, Anja

Publication date:
2017

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
Mazzoni, C., Tentor, F., Andersen, S. S. S., Nielsen, L. H., Keller, S. S., Müllertz, A., Marizza, P., & Boisen, A. (2017). *MICROCONTAINERS FOR INTESTINAL DRUG DELIVERY: in vivo and ex vivo study*. Abstract from Non-Invasive Delivery of Macromolecules Conference, San Diego, United States.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

MICROCONTAINERS FOR INTESTINAL DRUG DELIVERY: *in vivo* and *ex vivo* study

C. Mazzoni^a & F. Tentor^a, S. Strindberg^b, L. H. Nielsen^a, S. S. Keller^a, A. Müllertz^b, P. Marizza^a, A. Boisen^a

^a, Dept. of Micro- and Nanotechnology, Technical University of Denmark, Kongens Lyngby 2800, Denmark

^b, Dept. of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark

The oral administration route is the one most preferred by patients. The digestive system presents several challenges: the low gastric pH, the intestinal mucus and the presence of enzymes can all reduce the therapeutic effect of the active pharmaceutical ingredient (API). Capsules and tablets are commonly used dosage forms in clinical practice. Nevertheless, in these drug delivery systems (DDS), the API is released in an omnidirectional manner entailing an unavoidable loss of the therapeutic substance in the intestinal lumen. Microcontainers (Fig. 1 a) are micro-fabricated cylindrical reservoirs filled with the API which can be used as a multi-particulate system with an intrinsic unidirectional release due to their geometry¹. Hereby, we present the *in vivo* and *ex vivo* performances of microcontainers as DDS for ketoprofen chosen as poorly soluble model drug. Microcontainers were filled with polyvinyl pyrrolidone (PVP, 10⁴ Da) and loaded with ketoprofen by supercritical CO₂ assisted-impregnation². The cavities of the microcontainers were sealed with an enteric coating (Eudragit L100/dibutyl sebacate) deposited *via* spray coating to activate the drug release upon reaching the intestinal pH³. The DDS was characterized both *in vitro*, *in vivo* (Fig.1 b) and *ex vivo* (Fig. 1 c). The results suggest the suitability of the microcontainers as carriers for other APIs, such as insulin or the already *in vitro* tested Cyclosporin A.




Figure 1 – a) SEM image of a loaded and coated microcontainer; b) Plasma concentration-time profile of ketoprofen in orally dosed with the aforementioned DDS rats; c) Optical micrograph of microcontainers within rat's jejunum after oral administration (*ex vivo* study).

References

1. P. Marizza, and A. Boisen. *J Control Release*. 2014;173:1-9.
2. P. Marizza, and A. Boisen. *J Supercrit Fluids*. 2016;107:145-152.
3. L.H. Nielsen, and A. Boisen. *Biomed Microdevices*. 2015;17(3):1-7.